Table 2.
Rates of short-term adverse events in low-risk patients with or without imaging and laboratory indicators of right ventricular dysfunction or myocardial injury
| RV dysfunction (exposure) | Study population (n studies) | With RV dysfunction, % (95% CI) | Without RV dysfunction, % (95% CI) | |
|---|---|---|---|---|
| Early all-cause mortality | RV pressure overload (echo/CTPA) | 1597 (7) | 1.8 (0.9–3.5) | 0.2 (0.03–1.7) |
| Troponin | 1176 (11) | 3.8 (2.1–6.8) | 0.5 (0.2–1.3) | |
| BNP/NT-proBNP | — | — | — | |
| Early PE-related adverse outcome | RV pressure overload (echo/CTPA) | 1488 (6) | 3.7 (0.9–14.4) | 0.7 (0.06–6.4) |
| Troponin | 1137 (8) | 10.2 (7.2–14.3) | 0.6 (0.1–5.6) | |
| BNP/NT-proBNP | 1405 (6) | 5.4 (1.8–14.6) | 1.3 (0.6–2.6) |
The PE-related adverse outcome includes PE-related mortality, haemodynamic collapse, and/or recurrent venous thromboembolism.
BNP, B-type natriuretic peptide; CTPA, computed tomography pulmonary angiography; NT-proBNP, N-terminal pro-B-type natriuretic peptide; PE, pulmonary embolism; RV, right ventricular.